COSCIENS Biopharma Acquires Nualtis Corp for $15M: Oral Thin-Film Tech for Animal Health
Toronto, Ontario — September 10, 2026 – COSCIENS Biopharma Inc. (TSX: CSCI, OTCQB: CSCIF) today announced the acquisition of Nualtis Corp, a Montreal-based specialty pharmaceutical technology firm, for US$15 million in cash plus up to four earn-out payments equal to 10% of Nualtis EBITDA from 2027 to 2030. The deal includes Nualtis’s proprietary oral thin-film drug delivery technology, which has applications in both human and animal health markets exceeding US$100M annually.
Deal Structure & Financial Terms – Upfront Consideration
-
US$15 million in cash payable at closing (completed Sept 10, 2026).
Earn-Out Payments
-
Four annual payments (2027–2030), each equal to 10% of Nualtis EBITDA for the respective year.
-
Earn-outs are uncapped, providing upside potential if Nualtis exceeds profitability targets.
Strategic Partnership
-
Nualtis has an existing veterinary formulation (undisclosed active ingredient) developed in partnership with Covenant Animal Health Partners, targeting a >US$100M annual sales market.
-
COSCIENS will leverage Nualtis’s technology platform for both human and animal health applications, with priority given to veterinary products due to faster regulatory pathways.
Technology Overview: Oral Thin-Film Drug Delivery
Nualtis’s proprietary platform enables:
-
Rapid Dissolution: Thin-film strips dissolve in <30 seconds on the tongue, ideal for compliance-challenged populations (pediatric, geriatric, veterinary).
-
Enhanced Bioavailability: Bypasses first-pass metabolism, improving absorption of poorly soluble compounds.
-
Dose Flexibility: Easy to adjust potency by modifying film size or layering.
-
Stability: No refrigeration required; shelf life >24 months at ambient temperatures.
Veterinary Applications
-
Companion Animals: Pain management (NSAIDs), anxiety relief (gabapentin), chronic disease (thyroid, renal).
-
Livestock: Antibiotic alternatives, parasiticides, reproductive hormones.
-
Exotic Species: Reptiles, birds, small mammals (where pill administration is impractical).
Strategic Rationale for COSCIENS
1. Diversification Beyond Human Health
COSCIENS, traditionally focused on human CNS and metabolic disorders, gains immediate entry into the high-growth veterinary therapeutics market (CAGR 8.5% to 2030).
2. Faster Regulatory Pathways
Veterinary drugs often require shorter clinical trials and lower regulatory costs compared to human pharmaceuticals. Nualtis’s existing partnership with Covenant Animal Health Partners accelerates time-to-market.
3. Revenue Synergies
-
Near-term: Royalty income from Nualtis’s existing veterinary formulation (2027–2030).
-
Mid-term: Co-development of 3–5 new veterinary SKUs using thin-film technology (2028–2030).
-
Long-term: Licensing platform to Tier 1 animal health companies (Zoetis, Boehringer Ingelheim, Elanco).
Company Profiles
COSCIENS Biopharma Inc. (TSX: CSCI)
-
Founded: 2018
-
Headquarters: Toronto, Ontario, Canada
-
Focus: CNS disorders, metabolic diseases, novel drug delivery systems
-
Market Cap (Sept 10, 2026): ~CAD 85M
-
Cash on Hand: ~CAD 20M (pre-acquisition)
-
Key Pipeline: CS-101 (Parkinson’s), CS-202 (obesity), Nualtis thin-film platform (new)
Nualtis Corp
-
Founded: 2019
-
Headquarters: Montreal, Quebec, Canada
-
Focus: Oral thin-film drug delivery for human + animal health
-
Employees: ~15 (R&D-heavy)
-
Key Partners: Covenant Animal Health Partners (veterinary), undisclosed human pharma collaborators
-
Revenue (2025): ~US$2M (licensing + contract R&D)
Executive Commentary
“The acquisition of Nualtis represents a strategic inflection point for COSCIENS. Their oral thin-film technology is uniquely suited for veterinary applications, where compliance and ease of administration are critical. With Covenant Animal Health Partners as a collaborator, we have a clear path to commercialization in a >$100M market.”
— CEO, COSCIENS Biopharma (quoted in GlobeNewswire)
“Nualtis’s platform solves a fundamental challenge in animal health: getting medications into pets and livestock without stress or waste. Partnering with COSCIENS gives us the capital and regulatory expertise to scale rapidly.”
— CSO, Nualtis Corp (quoted in GlobeNewswire)
Financial Impact & Valuation
Source: Company filings, GlobeNewswire, analyst estimates
Market Context: Veterinary Drug Delivery Innovation
The Nualtis acquisition aligns with broader trends in veterinary pharmaceuticals:
-
Oral thin-film market (human + animal) projected to reach US$2.5B by 2030 (CAGR 12.3%).
-
Companion animal therapeutics growing at 9.1% CAGR (2026–2030), driven by pet humanization and chronic disease management.
-
Livestock antibiotic alternatives: Thin-film delivery of probiotics, phytogenics, and immune modulators gaining traction post-EU antibiotic bans.
Future Outlook
COSCIENS outlined a 3-phase roadmap for Nualtis integration:
 acquires Nualtis Corp for US$15M cash + earnouts. Deal includes veterinary oral thin-film formulations){kind=link}